A study found that combining an oncolytic virus with CD19-Chimeric Antigen Receptor-T (CAR-T) cells was effective in treating pancreatic cancer. The engineered virus successfully infected and expressed CD19 on tumor cells, leading to an increased immune response and cell killing when co-cultured with CD19-CAR-T cells. In combination therapy, the virus and CAR-T cells significantly reduced tumor size compared to control groups. These findings suggest a potential universal CAR-T cell strategy for solid tumors by leveraging oncolytic viruses.
Journal Article by Chen C, Park AK (…) Fong Y et 5 al. in J Am Coll Surg
Copyright © 2024 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.